In Pulmonary Fibrosis Awareness Month, I would like to share our recently published editorial:

🚨Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis🚨

#PulmonaryFibrosis #PFMonth #Cough #IPF🫁

https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.202305-483ED

UK TRADE (Selection):
International Personal Finance, Buy, +6.75 #IPF

Die idiopathische #Lungenfibrose #IPF ist eine #chronische Erkrankung mit unvorhersehbarem Verlauf. Sie entsteht durch eine gestörte Wundheilung der #Lunge nach kleineren Verletzungen auf zellulärer Ebene. Dabei kommt es zu einer gesteigerten Produktion und Anreicherung von #Bindegewebe.

Auszug aus:

http://patienten-bibliothek.de/_pb2015/pb/ratgeber/D//c.pdf#page=61

RT @KerriBerriKerri@twitter.com

🌟From Dr. Carl Reynolds et al.🌟
Occupational asbestos exposure alone does not⬆️risk of #IPF
👉asbestos+smoking interact➡️#IPF w/ MUC5B allele
66% cases/63% controls high/med exposure risk😬
8% v. high cumulative exposure😬
#AsbestosBan #CleanAir #CureIPF
https://oem.bmj.com/content/early/2023/01/12/oemed-2022-108404

RT @harshameghadri@twitter.com

A bit late share but a really cool work by @BREATH_Hannover@twitter.com @jonas_schupp@twitter.com @KaminskiMed@twitter.com and co-authors looking at Src inhibitors on reversing gene expression signatures in IPF using CLUE/L1000.

https://www.nature.com/articles/s41467-022-33193-0

#IPF #Bioinformatics #SingleCell

Do give it a read :)

RT @PilarRiveraOrt1@twitter.com

@REMAP_ILD@twitter.com @IPFdoc@twitter.com @leticiakawano@twitter.com @RogerJLewis@twitter.com @BerryConsultant@twitter.com @KaminskiMed@twitter.com @KerriBerriKerri@twitter.com @ActionPFwendy@twitter.com @pfsg_nireland@twitter.com @ActionPFcharity@twitter.com It is a privilege to be part of this fabulous team worldwide 🌎 @REMAP_ILD@twitter.com We are a great family 🤗🫁 I wish all of you a Happy 2023! 🎇🎉🎊 #ILD #IPF #CureIPF #teamwork

RT @YalePCCSM@twitter.com

Oxygen therapy needs to provided in way that helps patients & laws need to be changed to make this happen says Dr. Kahn @PeterKahnMD@twitter.com) a second year @YalePCCSM@twitter.com fellow & former @YaleIMed@twitter.com resident
(coauthors Anna Kowanko, Susan Jacobs)
#COPD #COVID19 #IPF
https://thehill.com/opinion/healthcare/3778239-the-reality-of-oxygen-therapy-in-2022/

Speak about leadership & advocacy! #OurPatientsNeedOxygen
#ThisIsOurLane
Kudos @PeterKahnMD@twitter.com & team!

RT @YalePCCSM@twitter.com

Oxygen therapy needs to provided in way that helps patients & laws need to be changed to make this happen says Dr. Kahn @PeterKahnMD@twitter.com) a second year @YalePCCSM@twitter.com fellow & former @YaleIMed@twitter.com resident
(coauthors Anna Kowanko, Susan Jacobs)
#COPD #COVID19 #IPF
https://thehill.com/opinion/healthcare/3778239-the-reality-of-oxygen-therapy-in-2022/

RT @dfellerk@twitter.com

Excited to be an official Pulmonary Fibrosis Foundation Care Center Network Site #DHMCPCCM #DHMC #dartmouth-hitchcock #PFF #IPF

👇🏼

RT @IPFdoc@twitter.com

@TamesideGroup@twitter.com @TobyMMaher@twitter.com @ILDIPFDoc_NI@twitter.com @PilarRiveraOrt1@twitter.com This is really 😎 study from @Paulwnoblemd@twitter.com & colleagues showing crucial importance of ZIP8 in #IPF which regulates zinc metabolism in key cells causing fibrosis. It DOES NOT show taking zinc helps #CureIPF. Further studies are required to show this! Perhaps @REMAP_ILD@twitter.com will help.

RT @KerriBerriKerri@twitter.com

@shapps999@twitter.com @KaminskiMed@twitter.com @DrPujaMehta1@twitter.com @PilarRiveraOrt1@twitter.com @jeffsparks@twitter.com @IPFdoc@twitter.com @bruno_crestani@twitter.com @NeumologiaPeru@twitter.com @DrFaican@twitter.com @Katerin16265046@twitter.com @mariamolinao@twitter.com @scott_matson@twitter.com @PhilippeDieude@twitter.com @jolenehfisher@twitter.com @CTS_SCT@twitter.com Agree. And also a different pt population than those with suspected #IPF

RT @drphilmol@twitter.com

Cough is a major problem for patients with ILD. Burden in CHP similar to #ipf @ImperialNHLI@twitter.com @ActionPFcharity@twitter.com @aluk_research@twitter.com #BTSWinter2022 https://twitter.com/actionpfwendy/status/1595347146907258880

🐦🔗: https://twitter.com/drphilmol/status/1595391416863178753

#Introduction Hoping to communicate high quality information about lung health and respiratory medicine.
#COPD
#Asthma
#Lung
#ILD
#IPF
#RespIsBest
#Bronchiectasis
#COVID

RT @PilarRiveraOrt1@twitter.com

@KaminskiMed@twitter.com @smlungpathguy@twitter.com @KerriBerriKerri@twitter.com @IPFdoc@twitter.com @leticiakawano@twitter.com Completely agree Naftali! New interventions and treatments for #IPF patients are necessary and urgent #CureIPF #teamwork

RT @PilarRiveraOrt1@twitter.com

@KaminskiMed@twitter.com @smlungpathguy@twitter.com @KerriBerriKerri@twitter.com @IPFdoc@twitter.com @leticiakawano@twitter.com 🧵 Some #IPF patients show functional stability, which may or may not be accompanied by clinical stability. More long-term (ideally global) real world studies are required on the effect of antifibrotic treatment in addition to what happens to the predicted FVC percentage. 🧵

RT @PilarRiveraOrt1@twitter.com

@KaminskiMed@twitter.com @smlungpathguy@twitter.com @KerriBerriKerri@twitter.com @IPFdoc@twitter.com @leticiakawano@twitter.com 🧵 However, the response of #IPF patients to antifibrotic treatment may be variable, depending on the time of initiation of treatment (stage/severity of the disease), comorbidities, and other risk factors of each patient (e.g., environmental and/or genetic factors). 🧵

RT @PilarRiveraOrt1@twitter.com

@KaminskiMed@twitter.com @smlungpathguy@twitter.com @KerriBerriKerri@twitter.com @IPFdoc@twitter.com @leticiakawano@twitter.com Hi everyone, very interesting discussion. Totally agree with @KaminskiMed@twitter.com In general, the effect of antifibrotic treatment in patients with #IPF is to slow down the progression of the disease, assessed from the functional point of view (change in percent predicted FVC). 🧵

🧵 Therefore my recommendation is not to look only at the FVC, because we could have an incomplete and not adequate view of the stage and prognosis of #IPF. Holistic and multidisciplinary approach above all, patients are our priority.

The predicted FVC percentage is important (whether you're calculating the absolute or relative difference in the short or long term), but it's not the only factor to consider. More #research is needed

For more information: https://pubmed.ncbi.nlm.nih.gov/33895005/

Many thanks

🧵 Obviously a detailed medical history is essential that includes risk factors or environmental exposures that the patient may have had, either due to their occupational history, place where they live, hobbies, etc.

We should also take into account the patient's comorbidities to assess their risk of disease progression. Only when we have evaluated all the aforementioned characteristics, we could be in a position to say the stage of #IPF and its need for antifibrotic treatment.
🧵

🧵 It is also important to assess the patient's symptoms (eg, dyspnea on exertion and cough), the radiological pattern on HRCT (especially if the pattern is usual interstitial pneumonia #UIP), and the extent of fibrosis.

In addition, it is important to have information about personal and family history that could be associated with familial pulmonary fibrosis and / or #telomere shortening syndrome.
🧵 #IPF #TRG #TelomereDysfunction